Traditional MedicareCoverageMedium impact
MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
Medicare/CMS - LCD·Endocrinology, ENT (Ear, Nose & Throat), General Surgery +1 more·Local Coverage Determination
Effective date
May 28, 2026
We identified it
Jun 17, 2026
Summary
Medicare has updated Local Coverage Determination L39720 for molecular testing used to assess thyroid nodule cancer risk. This policy change affects coverage criteria and billing requirements for thyroid nodule genetic testing, effective May 28, 2026.
Action Required
Before May 28, 2026: Billing team must review updated LCD L39720 requirements for thyroid nodule molecular testing coverage criteria. Update prior authorization workflows and documentation requirements for thyroid genetic testing. Verify patient eligibility meets new Medicare coverage standards before ordering tests.